Manajemen Ekstravasasi Kemoterapi
[Extravasasion Chemoteraphy Management]
Downloads
Extravasation is a problem for patient receiving chemotherapy. This will cause pain, ulcer, necrosis and might be a permanent disability. Extravasation is a leakage of a fluid or medicine to the surrounding subcutaneous tissue of the vein or vascular, that may cause skin or tissue necrotic. There was a wide span of incidence data of extravasation on the literature, between 0,01% and 11% reported from child to adult. Management of extravasation was based on proper maintenance of the intravenous (IV) line and application of cold or warm compresses, plus the use of antidotes when available. Antidotes for extravasation that have been shown to be useful are sodium thiosulfate for nitrogen mustard, dimethylsulfoxide for anthracyclines and mitomycin, and hyaluronidase for the vinca alkaloids. New treatments include dexrazoxane, sargramostim, and hyperbaric oxygen for doxorubicin extravasations. In order to improve patient service quality and reduce morbidity, every medical staff handle cancer patient receiving chemotherapy should have sufficient knowledge about how to manage extravasation event.
Markwick A. Extravasation Guidelines for Practice in Paediatric Wards. 2002. 1-7 p.
Unseld M, Thallinger C. ESMO HANDBOOK OF ONCOLOGICAL EMERGENCIES. 2nd ed. Pulla, Mariano Provencio Medical Oncology Department, Hospital Universitario Puerta de Hierro, Madrid S, editor. 2016. 58 p.
Hasting C. Treatment of chemoterapy extravasations. Hema tology/Oncology Handbook, St. Louis: Mosby; 2002. 197-198 p.
Dougherty. Intravenous management. The Royal Marsden Hospital Handbook of Cancer Chemotherapy, editor. 2005. 93-107 p.
Fidalgo JAP, Fabregat LG, Cervantes A, Margulies A, Vidall C, Roila F, et al. clinical practice guidelines Management of chemotherapy extravasation : ESMO – EONS Clinical Practice Guidelines " clinical practice guidelines. 2012;23(Supplement 7).
Goolsby T V., Lombardo FA. Extravasation of chemotherapeutic agents: Prevention and treatment. Semin Oncol. 2006;33(1):139–43.
Ener RA, Meglathery SB, Styler M. Extravasation of systemic hemato-oncological therapies. Vol. 15, Annals of Oncology. 2004. p. 858–62.
Kreidieh FY, Moukadem HA, El Saghir NS. Overview, prevention and management of chemotherapy extravasation. World J Clin Oncol [Internet]. 2016;7(1):87–97. Available from:http://www.ncbi.nlm.nih.gov/pubmed/26862492%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4734939
Naylor W. Extravasation wounds: aetiology and managementle. The Royal Marsden Hospital Handbook of Cancer Chemotherapy, editor. 2005. 109-111 p.
cassagnol m M bride a. Management of Chemotherapy Extravasation. Us pharm. 2009;3–11.
St Luke's Cancer Alliance N. Guidelines for Prevention and Management of Chemotherapy Extravasation. 2014. 1-18 p.
Jordan K, Behlendorf T, Mueller F SH. Anthracycline extravasation injuries: management with dexrazoxane. Ther Clin Risk Manag. 2009;361–6.
Schrijvers DL. Extravasation: a dreaded complication of chemotherapy. Ann Onco. 2003;
El-Saghir N, Otrock Z, Mufarrij A, Abou-Mourad Y, Salem Z, Shamseddine A AJ. Dexrazoxane for anthracycline extravasation and GM-CSF for skin ulceration and wound healing. Lancet Oncol. 2004;5:320–1.
Bertelli G, Gozza A, Forno GB, Vidili MG, Silvestro S, Venturini M, Del Mastro L, Garrone O, Rosso R DD. Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol. 1995;
Conde-Estévez D MAJ. Treatment of anthracycline extravasations using dexrazoxane. Clin Transl Oncol. 2014;6:11–7.
Hong WK, Bast RC, Hait WN, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF IE. Cancer Medicine. PMPH USA ltd. 2010. p. vol 8.
Al-Benna S, O'Boyle C HJ. Extravasation injuries in adults. ISRN Dermatol. 2013;
Haslik W, Hacker S, Felberbauer FX, Thallinger C, Bartsch R, Kornauth C, et al. Port-a-Cath?? extravasation of vesicant cytotoxics: Surgical options for a rare complication of cancer chemotherapy. Eur J Surg Oncol. 2015;41(3):378–85.
Lucchina S FC. Surgical vacuum-assisted closure for treatment of vinorelbine extravasation. Chin J Traumatol. 2009;12: 247-249.
Isci E, Canter HI, Dadaci M, Atilla P, Cakar AN, Kecik A. The efficacy of negative pressure wound therapy on chemotherapeutic extravasation ulcers: An experimental study. Indian J Plast Surg. 2014;47(3):394–400.
Gill AL, Bell CNA. Hyperbaric oxygen: Its uses, mechanisms of action and outcomes. Vol. 97, QJM - Monthly Journal of the Association of Physicians. 2004. p. 385–95.
Ali I, Rahis-Uddin, Salim K, Rather M a, Wani W a, Haque A. Advances in nano drugs for cancer chemotherapy. Curr Cancer Drug Targets. 2011;11(2):135–46.
Control D. Guidelines for the Management of Extravasation. 2016;1–11.
Copyright (c) 2019 Nur Nubli Julian Parade, Isnu Pradjoko
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.
JR (